Sitemap
June 05, 2010 Articles
Filter by Available Specialty
- Adding TRAIL-R1 agonist monocloncal antibody to chemotherapy combo did not improve response in advanced NSCLC
- ALK inhibitor crizotinib has high response rate in patients with ALK-positive NSCLC
- ARQ-197 plus erlotinib prolonged PFS in EGFR inhibitor naive NSCLC patients
- EADO: No difference between pegylated, conventional interferon alfa-2b for melanoma
- Ipilimumab improved OS by 34% in advanced, previously treated melanoma
- Paclitaxel plus carboplatin improved survival in older patients with advanced NSCLC
- Percutaneous hepatic perfusion with melphalan improved hepatic PFS in ocular, cutaneous melanoma
- Selenium did not prevent second primary tumor in NSCLC
- Targeted molecular therapy GDC-0449 well-tolerated in phase 1 trial of pediatric medulloblastoma